We would particularly monitor the different strategic agreements that this company could implement with other pharmaceutical companies and organisations with the aim of furthering research and innovations.
The GSK Group's shareholder base is partly made up of a number of large institutional shareholders, including The Vanguard Group with 2.98% of the shares, BlackRock Investment Management with 2.59%, BlackRock Fund Advisors with 2.56%, Norges Bank Investment Management with 2. 45%, Legal & General Investment Management with 2.13%, Schroder Investment Management with 1.42%, Capital Research & Management with 1.37%, Dodge & Cox with 1.34%, Capital Research & Management with 1.28% and Thredneedle Asset management with 1.26%.